ASCO 2024
Dec 13, 2024
AstraZeneca’s IMFINZI Archives Another Milestone — Becomes the First Immunotherapy for Limited-Stage Small-cell Lung Cancer
AstraZeneca has secured another approval for its cancer blockbuster IMFINZI (durvalumab), as the FDA has approved the PD-L1 inhibitor for patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent chemotherapy and radiation. This approval makes IMFINZI the ...
Read More...
Dec 09, 2024
How CDK4/6 Inhibitors Are Changing the Cancer Treatment Paradigm?
In the rapidly evolving landscape of cancer therapy, one class of drugs is making waves for its game-changing impact: CDK4/6 inhibitors. These revolutionary agents are rewriting the narrative for treating cancers driven by uncontrolled cell division, particularly hormone receptor-positive, HER2-negative breast canc...
Read More...
Jun 04, 2024
Moderna’s mRESVIA(R) FDA Approval; Novartis Scemblix® Phase III Data; Kite’s Tecartus for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Astellas’ Zolbetuximab Biologics License Application; CHMP Recommends AstraZeneca’s Tagrisso
FDA Greenlights Moderna's RSV Vaccine mRESVIA(R) Moderna, Inc. has announced that the FDA has approved mRESVIA (mRNA-1345), an mRNA-based vaccine for respiratory syncytial virus (RSV), to protect adults aged 60 and over from lower respiratory tract infections caused by RSV. This approval, granted under a breakth...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
